*ST春天公告称，公司股票在2026年1月30日、2月2日、2月3日连续3个交易日内日收盘价格跌幅偏离值 累计达12%，属异常波动。经自查，公司经营正常，无应披露未披露重大信息。公司2025年4月30日被 实施退市风险警示，预计2025年营收3.43-3.71亿元，扣非后为3.38-3.67亿元，净利润-0.44至-0.60亿元。 年审会计师无法确定扣除特定收入后营收超3亿及能否消除退市指标，若预付借款无法收回，将出具无 法表示意见报告致公司股票终止上市。 ...

*ST正平公告称，2025年9月1日至2026年2月3日公司股价累计涨幅117.84%，期间剧烈波动。公司基本 面未变，但存在多项风险。一是股价波动积累高交易风险；二是2025年末净资产可能为负，触发退市； 三是2024年度审计非标意见消除工作未完成，若2025年继续被出具非标意见将面临终止上市风险。此 外，公司业绩持续亏损，2024年营收13.62亿元，归母净利润 -4.84亿元；2025年前三季度营收6.52亿 元，归母净利润 -0.99亿元。 ...

Core Viewpoint - The company *ST WanFang has experienced significant stock price volatility, with a cumulative decline of 13.31% over three consecutive trading days, indicating abnormal fluctuations [1] Financial Performance - The company anticipates a revenue range of 200 to 250 million yuan for the fiscal year 2025, with a net revenue (after deductions) expected to be between 150 to 200 million yuan [1] - Both total profit and net profit are projected to be negative, with revenues falling below 300 million yuan, which may trigger financial delisting scenarios [1] Regulatory Issues - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since July 2025, and if administrative penalties are imposed that meet certain criteria, it may face mandatory delisting for significant violations [1] - There is a risk that the audit report for the fiscal year 2025 may be issued with a qualified opinion, which could lead to the termination of the company's stock listing [1]

这是一场保壳的极速狂奔，仅24%的ST股业绩向好，多只ST股拉响了退市警报。这些公司大多存在被 出具非标年报、利润亏损、扣除后营业收入为负值、期末净资产为负值等情况，部分公司遭立案调查或 被处罚。 每当年报过后，就会有一批因业绩再度不达标的风险警示股黯然挥手资本市场，而业绩预告，往往成为 市场观察这些公司命运走向的重要风向标。 Wind数据显示，截至2月2日，178只风险警示股中，已有176只发布了业绩预告，其中。93只退市风险 警示股已全部发布业绩预告。 这是一场保壳的极速狂奔，仅24%的ST股业绩向好，多只ST股拉响了退市警报，如*ST岩石 （600696.SH）、*ST精伦（600355.SH）、*ST观典（688287.SH）等均称，公司股票可能被终止上市。 这些公司大多存在被出具非标年报、利润亏损、扣除后营业收入为负值、期末净资产为负值等情况，部 分公司遭立案调查或被处罚。 退市制度是市场新陈代谢的重要一环，自退市新规发布实施以来，资本市场正加速形成"应退尽退、及 时出清"的常态化退市格局。 仅24%ST股业绩向好 退市警报已拉响 在亏损依旧的ST股中，部分已提前明确触及财务类退市指标，如*ST岩石 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 一、退市警报拉响 2026年1月31日，ST岭南（维权）发布《2025年年度业绩预告》，ST岭南的财务指标同时触及了《深圳 证券交易所股票上市规则》第9.3.1条中的两项退市红线：最近一个会计年度的利润总额、净利润和扣非 净利润三者孰低为负值，且扣除后的营业收入低于3亿元；同时，期末净资产也为负值。 根据《深圳证券交易所股票上市规则》相关规定，公司股票交易可能在披露《2025年年度报告》后被实 施退市风险警示，股票简称前将冠以"*ST"字样。 ST岭南的情况尤为复杂。该公司此前已连续三年亏损，累计亏损超过36亿元。2024年，其内部控制审 计报告被年审会计师事务所出具了否定意见。 随后在2025年9月，公司及原控股股东收到中国证券监督管理委员会出具的《立案告知书》，因涉嫌信 息披露违法违规，中国证监会已正式决定对公司及原控股股东立案。 二、立案或早有端 ...

业绩大幅下滑主要受三方面因素影响：主营业务方面，公司核心产品环境在线监测用质谱仪市场受政府 采购周期影响处于深度调整期，同时新产品收入未能弥补传统业务下滑，加之公司主动放弃部分高风险 订单导致收入收缩；资产减值方面，公司对存货及部分长期资产计提减值准备；此外，政府补助确认金 额减少及递延所得税资产转回也对利润形成拖累。由于初步测算的扣非前后净利润孰低者为负值，且扣 除类营业收入低于1亿元，公司触及《上海证券交易所科创板股票上市规则》规定的退市风险警示情 形，可能在2025年年度报告披露后被实施*ST处理。 南方财经2月2日电，禾信仪器(688622.SH)2026年1月31日发布了2025年年度业绩预亏公告及首次退市风 险提示性公告。公告显示，公司预计2025年年度归属于母公司所有者的净利润约为-8,900万元，同比大 幅下降93.52%；扣除非经常性损益后的净利润约为-9,300万元，同比下降47.39%。营业收入预计为9,700 万元，同比下降逾五成，扣除与主营业务无关的收入后约为9,000万元，低于1亿元。 同日，禾信仪器已收到关于业绩预告事项的监管工作函，监管类型为监管工作函，涉及对象为上市公 司。 ...

伴随2025年业绩预告密集发布，一批上市公司拉响退市风险"警报"。 据上海证券报初步统计，近期，已有*ST观典、*ST岩石、*ST精伦、*ST春天等多家*ST公司发布公 告，提示投资者关注退市风险。其中，*ST岩石、*ST精伦已明确触及财务类退市指标，预计2025年年 报披露后终止上市。*ST太和等公司的财务指标则暂时"踩线达标"，但会计师均不能确定其2025年扣除 后的营业收入超过3亿元，仍存在退市风险隐患。 业内人士认为，自退市新规发布实施以来，市场对绩差公司的出清力度持续加大。在监管层持续强化常 态化退市机制的背景下，进退有序、及时出清的格局正加速形成。 多家*ST公司退市风险高悬 记者注意到，退市新规收紧了财务类退市指标，将主板亏损公司的营业收入指标从1亿元调高至3亿元， 进一步加大"壳公司"出清力度。在此背景下，一批2025年业绩预期不佳的*ST公司，面临触发组合类财 务退市指标的风险，"保壳"压力陡增。 以*ST岩石、*ST精伦为例，据其披露的2025年业绩预告，两家公司收入均不足3亿元且利润亏损，触及 组合类财务退市指标，拉响退市风险"警报"。 以*ST熊猫为例，公司年审会计师出具专项说明表示非 ...

Core Viewpoint - A number of listed companies are raising alarms about delisting risks as they release their 2025 performance forecasts, with several *ST companies already indicating they may not meet financial standards necessary to remain listed [1][2]. Group 1: Financial Performance and Delisting Risks - Several *ST companies, including *ST Guandian, *ST Yanshi, *ST Jinglun, and *ST Chuntian, have issued warnings about delisting risks due to poor financial performance [1]. - *ST Yanshi and *ST Jinglun have explicitly reached financial delisting indicators, with both companies expected to report revenues below 300 million yuan and losses in 2025 [2]. - *ST Yanshi forecasts revenues between 48 million to 60 million yuan and net losses between 180 million to 250 million yuan, indicating a significant deterioration in operational conditions [2][3]. Group 2: Audit Opinions and Compliance Issues - Companies like *ST Chun Tian and *ST Mu Bang are facing dual delisting risks due to both financial indicators and non-standard audit opinions, with auditors unable to confirm if their adjusted revenues will exceed 300 million yuan [4]. - *ST Jinglun's revenue is projected at 86.22 million yuan, which is below the 300 million yuan threshold, and the company is also facing scrutiny due to reliance on a single client for its new business [3]. - Non-standard audit opinions often indicate issues such as financial misreporting or severe doubts about a company's ability to continue as a going concern, which can trigger delisting [3][6]. Group 3: Regulatory Environment and Market Reactions - The tightening of delisting regulations has increased pressure on underperforming companies, with the revenue threshold for main board loss-making companies raised from 10 million to 30 million yuan [2]. - Regulatory authorities maintain a strict stance against "shell company" behaviors, as evidenced by the investigation into *ST Changyao for financial data misrepresentation, which could lead to severe penalties and delisting [8]. - The market is witnessing a trend of orderly and timely exits for underperforming companies, reflecting a shift towards a more stringent delisting mechanism [1][2].

Core Viewpoint - *ST HuKe's stock price increased by 11.7% to 4.01 yuan, with a total market value of 1.319 billion yuan, ranking 13th in the trade sector and 5175th in the A-share market [1] Performance Disclosure Highlights - The company expects 2025 annual operating revenue to be between 7.5 million and 11 million yuan, with the same range for net profit attributable to shareholders estimated between 3.9 million and 5.8 million yuan [1][3] - The net profit after deducting non-recurring items is projected to be between 280,000 and 420,000 yuan [1] Company Announcement Summary - The company received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws [1][3] - If the net profit for 2025 is negative and revenue is below 300 million yuan, the company's stock will be delisted [1][3] - The former controlling shareholder's fund occupation balance is 348.61 million yuan, accounting for 921.63% of the latest audited net assets [1][3] - The company has made a provision for bad debts of 89.9% on prepaid petrochemical payments, indicating further impairment risks [1]

Core Viewpoint - *ST Sailong (SZ002898) is facing significant operational and governance challenges, highlighted by the resignation of two audit firms and a projected net loss for 2025, raising concerns about its potential delisting risk [1][5][6]. Group 1: Audit Firm Resignation - The company received a joint letter from three independent directors urging management to explain the reasons behind the recent resignations of two audit firms, which are critical for the company's annual financial reporting [1][2]. - The resigning firms are Deloitte Touche Tohmatsu and Beijing Guofu Jiaying, with Deloitte citing heavy workload and personnel changes as reasons for its resignation [3][4]. - The independent directors emphasized the need for a thorough explanation of the circumstances surrounding the resignations and requested documentation related to the communications with the audit firms [4][5]. Group 2: Financial Performance - *ST Sailong forecasts a net loss of between 91 million to 151 million yuan for 2025, with a projected revenue of 4.1 billion to 5.3 billion yuan, and a net revenue after deductions expected to be between 3.6 billion to 4.6 billion yuan [5][6]. - The company attributes its poor performance to intensified market competition and difficulties in customer acquisition, leading to a significant decline in sales revenue and gross margin [5][6]. - The company has also made provisions for impairment on fixed assets, intangible assets, and development expenditures related to its pharmaceutical business [5]. Group 3: Delisting Risk - Due to the negative net profit forecast, if the audited revenue falls below 300 million yuan or if the financial report receives a qualified or adverse opinion, the company faces a risk of being delisted [6]. - The company has previously announced plans to alleviate financial pressure through a debt-to-equity swap and the public transfer of its wholly-owned subsidiary, but there has been no significant progress reported as of January 30 [6].